At the news
? NEUTRALIMPACT 5/10 8-K filed Jun 29, 2026 at 07:06 ET
BioCryst is discontinuing its internal discovery programs and closing its Birmingham, Alabama research facility by year-end 2026, shifting to an external innovation model. The restructuring lowers 2026 non-GAAP operating expense guidance by $30M to $420-440M, while revenue guidance of $635-660M is reaffirmed. Phase 3 ALPHA-ORBIT enrollment for navenibart is complete with top-line data expected in Q3 2027, and the manufacturing delay for ORLADEYO oral pellets is resolved with availability in early August.
- Board approved plan to discontinue internal discovery programs and close Birmingham Discovery Center of Excellence facility by end of 2026.
- Restructuring costs (contract termination, lease termination, severance, etc.) are not yet estimable; an amended 8-K will be filed when determined.
- 2026 non-GAAP operating expense guidance reduced from $450-470M to $420-440M.
- 2026 ORLADEYO revenue guidance reaffirmed at $625-645M; total company revenue guidance reaffirmed at $635-660M.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access